CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.
The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of cartilage/osteochondral defects in osteoarthritic knees and in knees without degenerative changes. This marks the first approved study of broad indications using a single implant.
In early 1Q16, the company completed a US $15MM financing round to support manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical Ventures and Peregrine Ventures.
CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.
The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of...
CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.
The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of cartilage/osteochondral defects in osteoarthritic knees and in knees without degenerative changes. This marks the first approved study of broad indications using a single implant.
In early 1Q16, the company completed a US $15MM financing round to support manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical Ventures and Peregrine Ventures.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
